Immunogenicity and Safety of Vi Capsular Polysaccharide Typhoid Vaccinein Healthy Persons in Korea : Immunogenicity and Safety of Vi Capsular Polysaccharide Typhoid Vaccinein Healthy Persons in Korea
Immunogenicity and Safety of Vi Capsular Polysaccharide Typhoid Vaccinein Healthy Persons in Korea
- 주제(키워드) Vi capsular polysaccharide typhoid vacine , immunogenicity , safetyTyphoid fever is a systemic bacterial infectious diseasecaused by Salmonella enterica serotype Typhi. Globally , 17 million people are annually infected by the bacteriumand more than 600
- 발행기관 한국미생물·생명공학회
- 발행년도 2007
- 총서유형 Journal
- UCI G704-000169.2007.17.4.018
- KCI ID ART001184626
- 본문언어 영어
초록/요약
The purpose of this study was to evaluate theimmunogenicity and safety of Salmonela Typhi Vi capsularpolysaccharide vaccine (Vi vaccine) in Korea. Theimmunogenicity of a single dose of Vi vacine was evaluatedin 157 subjects (75 children and 82 adults) before and at 1, 6,and 12 months after vaccination. Imunogenicity was measuredwith a passive hemagglutination assay (PHA), quantified asgeometric mean titers (GMTs) and seroconversion rates. Thesafety of the vacine was investigated by determining adversereactions occuring within 4 h, 3 days, and 1 month aftermonth after vaccination was 96.92% and 89.02%, respectively.In the case of children, the GMTs of Vi antibodies beforevaccination were 5.87±1.34 and 142.59±2.39 at one monthafter vaccination. For adults, the GMTs before and one monthafter vaccination were 5.58±1.28 and 58.56±3.67, respectively.Vi antibodies persisted for as long as 6 and 12 months aftervaccination. All adverse reactions in adults and children wereminor and did not require treatment. The Vi CPS vaccine was safeand imunogenic in adults and children older than 5 years.
more